New diagnostic faecal test could identify colorectal cancer

May 30, 2002

Authors of a research letter in this week's issue of THE LANCET describe a new technique where the detection of a specific protein in faeces could be a marker for colorectal cancer.

Colorectal cancer is a common disease (causing around 500,000 deaths each year worldwide), and screening methods that are more reliable than colonoscopy and faecal-blood assessment are needed for earlier disease detection. Nicholas Coleman and colleagues from the MRC Cancer Cell Unit, Cambridge, UK, aim to develop a non-invasive, stool-based assessment that can identify a specific protein - minichromosome maintenance protein 2 (MCM2) - which is present in cancerous colorectal cells but not normal cells.

In a clinical study, the investigators detected MCM2-positive cells from 37 of 40 patients known to have colorectal cancer; there was no detection of the protein in any of the 25 healthy individuals (the control group).

Nicholas Coleman comments: "These findings suggest that detection of MCM2 in colonocytes retrieved from the faecal surface might be of value in the non-invasive diagnosis of malignant colorectal disease. The conditions of this study do not represent those of a general screening setting, and our findings might have differed in a population with a higher frequency of cancers of the right-side of the colon. Nevertheless, despite the requirement for rapid stool processing, our approach might ultimately prove suitable for population screening, either alone or in combination with other tests."
Contact: Dr Nicholas Coleman, MRC Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge CB2 2XZ, UK; T) +44 (0)1223 763285; M) +44 (0)7900 596465; F) +44 (0)1223 763284; E)


Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to